Kazia Therapeutics Limited (NASDAQ: KZIA) has announced results from an expanded-access case involving a patient with metastatic triple-negative breast cancer (TNBC) treated with a combination of the company's investigational pan-PI3K/mTOR inhibitor, paxalisib, alongside immunotherapy and chemotherapy. Imaging conducted after three weeks of treatment showed an 86% reduction in overall tumor burden. The findings were reported by the company and are consistent with the approach being evaluated in Kazia's ongoing Phase 1b trial, which is assessing paxalisib in combination with pembrolizumab (Keytruda®) and chemotherapy in advanced breast cancer. The company has not indicated plans for a future presentation of these results.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN89222) on October 02, 2025, and is solely responsible for the information contained therein.